UC s Research Teamwork Brings Inventions Closer to Market
The annual report of invention disclosures at the
Anne Chasser, in only her second year as UCs associate vice president for technology transfer and commercialization, says that during 200506, UC generated more invention disclosures and identified more collaboration among its various colleges and more commercial activity involving UC technology than ever before.
This years Intellectual Property Office report, says Sandra Degen, PhD, vice president of research, shows that innovation is alive and well at UC, which reflects our commitment to be a major player among the worlds academic institutions not only in research, education and health care delivery, but as a business driver too.
The big story in this years report, says Chasser, is the fact that more collaboration is occurring across all campus colleges. Funding sources like the National Institutes of Health and the National Science Foundation, from which we get 85 percent of our research support, are now focusing on interdisciplinary collaboration as one of their major criteria. Collaboration is the future in terms of obtaining research funding, and were good at it.
Released yesterday, the report cites the example of Xanthostat Diagnostics Inc., a Cincinnati-based start-up company that is developing technology to improve detection of bleeding in the brain. The device evolved from collaboration between Joseph Clark, PhD, of UCs neurology department in the
This year, Chassers office reports 116 invention disclosurespatentable discoveries made by UC faculty, staff or students while conducting research at the university. Of these disclosures, about 20 percent were interdisciplinary collaborations, compared with only 1 percent last year.
The 116 disclosures also represented a 30 percent increase in overall disclosures compared with last year.
Deal flow, the amount of commercial activity involving UCs intellectual property, increased from 17 deals last year to 24 in 200506, and patents issued on UC-generated ideas rose from nine to 11, Chasser reports.
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Engineering professor named KEEN Fellow
August 31, 2026
Dhuree Seth, assistant professor educator in the Department of Aerospace Engineering, is one of 30 engineering faculty members nationwide who were named 2026 KEEN Engineering Unleashed Fellows. The University of Cincinnati College of Engineering and Applied Science has been a partner of the Kern Entrepreneurial Engineering Network (KEEN) since 2024. Seth has been part of KEEN since she was a PhD student more than 10 years ago.